Large cell neuroendocrine carcinoma
diseaseOn this page
Also known as large cell NEClarge-cell neuroendocrine carcinomaLCNEC
Summary
Large cell neuroendocrine carcinoma (MONDO:0005057) is a cancer (an umbrella term covering 6 Mondo subtypes) and 7 clinical trials. Top therapeutic interventions include cabozantinib, dexamethasone, and enasidenib. A subtype of neuroendocrine carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | large cell neuroendocrine carcinoma |
| Mondo ID | MONDO:0005057 |
| EFO | EFO:0000563 |
| DOID | DOID:0050872 |
| ICD-11 | 1278312485 |
| NCIT | C6875 |
| UMLS | C1265996 |
| MedGen | 220402 |
| GARD | 0024145 |
| Is cancer (heuristic) | yes |
Also known as: large cell NEC · large cell neuroendocrine carcinoma · large-cell neuroendocrine carcinoma · LCNEC
Disease family
This is a subtype of neuroendocrine carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › neuroendocrine carcinoma › large cell neuroendocrine carcinoma
Related subtypes (11): small cell carcinoma, anal canal neuroendocrine neoplasm, pancreatic endocrine carcinoma, combined lung carcinoma, malignant adrenal gland pheochromocytoma, liver neuroendocrine carcinoma, medullary thyroid gland carcinoma, goblet cell carcinoma, cutaneous neuroendocrine carcinoma, thymic neuroendocrine carcinoma, vulvar neuroendocrine carcinoma
Subtypes (6): thymic large cell neuroendocrine carcinoma, ovarian large-cell neuroendocrine carcinoma, breast large cell neuroendocrine carcinoma, pulmonary large cell neuroendocrine carcinoma, cervical large cell neuroendocrine carcinoma, pancreatic large cell neuroendocrine carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| PHASE1/PHASE2 | 2 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03728361 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer |
| NCT03866382 | PHASE2 | RECRUITING | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
| NCT04079712 | PHASE2 | ACTIVE_NOT_RECRUITING | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors |
| NCT06176989 | PHASE2 | RECRUITING | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors |
| NCT07278479 | PHASE1/PHASE2 | RECRUITING | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors |
| NCT02709889 | PHASE1/PHASE2 | TERMINATED | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors |
| NCT04452292 | Not specified | COMPLETED | Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABOZANTINIB | 4 | 4 |
| DEXAMETHASONE | 4 | 1 |
| ENASIDENIB | 4 | 1 |
| ROVALPITUZUMAB TESIRINE | 3 | 1 |